Cargando…
Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex
BACKGROUND: Survivin and XIAP are two important members of the inhibitor of apoptosis protein family and have been considered as potential targets for cancer treatment due to their overexpression in large variety of cancers including colorectal cancer. It has been reported that survivin and XIAP can...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203900/ https://www.ncbi.nlm.nih.gov/pubmed/32381104 http://dx.doi.org/10.1186/s13046-020-01581-3 |
_version_ | 1783529959238664192 |
---|---|
author | Fang, Wanxia Che, Xiaofang Li, Guohui Wang, Anhui Wang, Yizhe Shi, Xiaonan Hou, Kezuo Zhang, Xiaojie Qu, Xiujuan Liu, Yunpeng |
author_facet | Fang, Wanxia Che, Xiaofang Li, Guohui Wang, Anhui Wang, Yizhe Shi, Xiaonan Hou, Kezuo Zhang, Xiaojie Qu, Xiujuan Liu, Yunpeng |
author_sort | Fang, Wanxia |
collection | PubMed |
description | BACKGROUND: Survivin and XIAP are two important members of the inhibitor of apoptosis protein family and have been considered as potential targets for cancer treatment due to their overexpression in large variety of cancers including colorectal cancer. It has been reported that survivin and XIAP can synergistically inhibit apoptosis by forming survivin-XIAP complex. In this study, we aimed to design a peptide that targets the survivin-XIAP complex and elucidate its anticancer mechanisms in colorectal cancer cells. METHODS: We designed and synthetized Sur-X, the peptide targeting survivin-XIAP complex. The anticancer effects of Sur-X were evaluated both in vitro and in vivo. The underlying molecular mechanisms were also investigated. RESULTS: Sur-X exhibited potent inhibitory effects on four colorectal cancer cell lines HCT116, HCT15, RKO and HT29, but not on human peritoneal mesothelial cell line HMrSV5. Mechanistically, Sur-X induced Caspase 9-dependent intrinsic apoptosis in colorectal cancer cells by disrupting the survivin-XIAP complex and subsequently destabilizing survivin and XIAP. Interestingly, we found that Sur-X can also promote necroptosis. It was demonstrated that Sur-X destroyed the interaction between XIAP and TAB1 in the XIAP-TAB1-TAK1 complex, leading to the instability of TAK1, an endogenous necroptosis inhibitor. Subsequently, the accelerated degradation of TAK1 attenuated its inhibition on necroptosis in colorectal cancer cells. Moreover, knockdown of TAK1 restored the sensitivity of TAB1-overexpressing colorectal cancer cells to Sur-X-induced necroptosis. The in vivo pro-apoptotic effect of Sur-X was confirmed by the enhanced TUNEL staining and the decreased expression of survivin and XIAP in tumor tissues from xenograft mouse models. In addition, extensive necrosis and weaker MLKL expression in xenografts provided evidence for the in vivo pro-necroptotic effect of Sur-X. CONCLUSIONS: Peptide Sur-X exhibits strong pro-apoptotic and pro-necroptotic effects in colorectal cancer cells and has a high clinical translation potential in the treatment of colorectal cancer. |
format | Online Article Text |
id | pubmed-7203900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72039002020-05-12 Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex Fang, Wanxia Che, Xiaofang Li, Guohui Wang, Anhui Wang, Yizhe Shi, Xiaonan Hou, Kezuo Zhang, Xiaojie Qu, Xiujuan Liu, Yunpeng J Exp Clin Cancer Res Research BACKGROUND: Survivin and XIAP are two important members of the inhibitor of apoptosis protein family and have been considered as potential targets for cancer treatment due to their overexpression in large variety of cancers including colorectal cancer. It has been reported that survivin and XIAP can synergistically inhibit apoptosis by forming survivin-XIAP complex. In this study, we aimed to design a peptide that targets the survivin-XIAP complex and elucidate its anticancer mechanisms in colorectal cancer cells. METHODS: We designed and synthetized Sur-X, the peptide targeting survivin-XIAP complex. The anticancer effects of Sur-X were evaluated both in vitro and in vivo. The underlying molecular mechanisms were also investigated. RESULTS: Sur-X exhibited potent inhibitory effects on four colorectal cancer cell lines HCT116, HCT15, RKO and HT29, but not on human peritoneal mesothelial cell line HMrSV5. Mechanistically, Sur-X induced Caspase 9-dependent intrinsic apoptosis in colorectal cancer cells by disrupting the survivin-XIAP complex and subsequently destabilizing survivin and XIAP. Interestingly, we found that Sur-X can also promote necroptosis. It was demonstrated that Sur-X destroyed the interaction between XIAP and TAB1 in the XIAP-TAB1-TAK1 complex, leading to the instability of TAK1, an endogenous necroptosis inhibitor. Subsequently, the accelerated degradation of TAK1 attenuated its inhibition on necroptosis in colorectal cancer cells. Moreover, knockdown of TAK1 restored the sensitivity of TAB1-overexpressing colorectal cancer cells to Sur-X-induced necroptosis. The in vivo pro-apoptotic effect of Sur-X was confirmed by the enhanced TUNEL staining and the decreased expression of survivin and XIAP in tumor tissues from xenograft mouse models. In addition, extensive necrosis and weaker MLKL expression in xenografts provided evidence for the in vivo pro-necroptotic effect of Sur-X. CONCLUSIONS: Peptide Sur-X exhibits strong pro-apoptotic and pro-necroptotic effects in colorectal cancer cells and has a high clinical translation potential in the treatment of colorectal cancer. BioMed Central 2020-05-07 /pmc/articles/PMC7203900/ /pubmed/32381104 http://dx.doi.org/10.1186/s13046-020-01581-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Fang, Wanxia Che, Xiaofang Li, Guohui Wang, Anhui Wang, Yizhe Shi, Xiaonan Hou, Kezuo Zhang, Xiaojie Qu, Xiujuan Liu, Yunpeng Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex |
title | Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex |
title_full | Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex |
title_fullStr | Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex |
title_full_unstemmed | Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex |
title_short | Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex |
title_sort | sur-x, a novel peptide, kills colorectal cancer cells by targeting survivin-xiap complex |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203900/ https://www.ncbi.nlm.nih.gov/pubmed/32381104 http://dx.doi.org/10.1186/s13046-020-01581-3 |
work_keys_str_mv | AT fangwanxia surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT chexiaofang surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT liguohui surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT wanganhui surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT wangyizhe surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT shixiaonan surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT houkezuo surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT zhangxiaojie surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT quxiujuan surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex AT liuyunpeng surxanovelpeptidekillscolorectalcancercellsbytargetingsurvivinxiapcomplex |